Morgan Stanley Highlights - Interesting implication | ACAD Message Board Posts

ACADIA Pharmaceuticals Inc.

  ACAD website


    30% off entry-level Bronze Patron packages (retails for $250 - reduced to $175)
    includes 2 yrs of Premium Plus service & locks in 30% discount for any future Patron upgrades

    Only 35 spots available (first come, first served)

    BONUS: Purchase your spot over the next 24 hrs & get an extra year of Premium Plus service absolutely free! 

    CLICK HERE to become a Bronze Patron now 

ACAD   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  15620 of 16403  at  9/12/2019 1:05:38 AM  by


 In response to msg 15619 by  longusa
view thread

Re: Morgan Stanley Highlights - Interesting implication

Good points, Long. Given that ACAD has revised FY guidance upwards twice already, and given 2Q sales that were close to $12 million higher than most analyst estimates, might UPOD be a significant factor here?
If this chart is accurate, the highest estimate for 2020 sales is $693.18 million. If this figure is anywhere close to being accurate, Nuplazid sales next year will mirror sales of Seattle Genetics' lead drug Adcetris this year. (SGEN's market cap is about $12 billion.)
Something people are overlooking is that the FDA has admonished doctors that there is only 1 approved drug for PDP (it did this in Sept. last year), and for many years has warned against antipsychotic use in DRP. Scripts will not be written off-label in DRP because they are cheaper than Nuplazid. So unlike the crowded spaces of depression and schizophrenia, the PDP/DRP markets will essentially belong to Acadia.
We've done this before, but DRP calcs are always interesting: e.g., 8% penetration of a 1.2 million market factoring in a modest price cut (Cowen sees it as possible) for a yearly cost of $30,000 yields $2.88 billion in sales, which is about half of ACAD's current market cap.
Lastly, if one of the big pharmas offered $12 billion for the company -- about $82/share -- do you think the Bakers would go for it? An uncertain political climate in the coming years might be one incentive for them to take such a proposal seriously.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 12     Views: 434
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
15623 Re: Morgan Stanley Highlights - Interesting implication longusa 8 9/12/2019 2:47:01 AM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by